Home/Filings/4/0001213900-23-074482
4//SEC Filing

McGovern Jr. Donald A. 4

Accession 0001213900-23-074482

CIK 0001690080other

Filed

Sep 5, 8:00 PM ET

Accepted

Sep 6, 6:28 PM ET

Size

10.4 KB

Accession

0001213900-23-074482

Insider Transaction Report

Form 4
Period: 2023-09-04
Transactions
  • Award

    Common Stock

    2023-09-04+25,18655,285 total
  • Award

    Non-Qualified Stock Option (right to buy)

    2023-09-04+44,77644,776 total
    Exercise: $0.67From: 2023-09-04Exp: 2033-09-04Common Stock (44,776 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2023-09-04+15,00015,000 total
    Exercise: $0.67Exp: 2033-09-04Common Stock (15,000 underlying)
Footnotes (4)
  • [F1]Issued in consideration for serving on the Board of Directors, as Lead Director, Chairman of the Audit Committee, and as a Member of the Compensation Committee and of the Risk, Safety and Regulatory Committee of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
  • [F2]Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
  • [F3]The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.
  • [F4]Granted in consideration for serving as Lead Director of the Company during 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

Issuer

180 Life Sciences Corp.

CIK 0001690080

Entity typeother

Related Parties

1
  • filerCIK 0001706276

Filing Metadata

Form type
4
Filed
Sep 5, 8:00 PM ET
Accepted
Sep 6, 6:28 PM ET
Size
10.4 KB